Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric sotatercept in pulmonary arterial hypertension
NL-OMON53701Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co. Primary endpoints: Safety and tolerability of sotatercept over 24 weeks of treatment and Pharmacokinetics of sotatercept over 24 weeks of treatment. Started Dec 2023; status: recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON53701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53701.